直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Ad Law Buzz Blog

Supreme Court to Explore Tension between FDA Labelling Laws and False Advertising under the Lanham Act

February 24, 2014

Authored and Edited by B. Brett Heavner

On January 10, 2014, the Supreme Court agreed to hear the appeal in  POM Wonderful v Coca-Cola.  This case explores the tension between how the FDA [Food and Drug Administration] deals with factual statements on labelling versus how the Lanham Act, which governs trade mark law and false advertising law, deals with factual statements on labelling.  At trial and then on appeal, the courts below took the view that the mere existence of specific regulations by the FDA relating to labelling preempts the ability of a private company to sue for false statements in the labelling under the Lanham Act. The Supreme Court will determine whether that is a correct interpretation of the FDA regulations.

The case involves a dispute between Coca-Cola's Minute Maid group and POM Wonderful relative to a Minute Made fruit beverage labelled as “pomegranate and blueberry” although made primarily from apple juice.  FDA regulations allow juices to feature the principle flavoring element on the label, even where a beverage is not comprised primarily of that juice.

Whereas POM Wonderful contends that FDA rules should not protect a confusing or misleading lay out or label, Minute Maid takes the position that FDA rules should be a complete defense to the labelling of its beverage.

The key question raised in the appeal is whether a Lanham Act suit contesting the truth of labelling that complies with FDA regulations amounts to an attempt at private enforcement of FDA regulations or, alternatively, an attempt to second guess FDA regulations.  If the latter, the Lanham Act false advertising claim may be pre-empted.

A decision by the Supreme Court’s decision could lay the groundwork for determining when a Lanham Act false-advertising claim can move forward in the face of regulation in that same field. The decision is likely to have significant impact not only on the pharmaceutical and food and beverage industry, but also on other industries where the government regulates advertising and labelling. Stay tuned.

Related Practices

Trademark and Brand Management

Advertising

Contacts

B. Brett Heavner
Partner
Washington, DC
+1 202 408 4073
Email

Copyright © 2014 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

Articles

COPPA’s Amended Rule Is Now in Full Effect: What Operators Need to Know

May 15, 2026

Webinar

Implementation of Long-Arm Jurisdiction by the UPC Court and German National Courts: Strategic Considerations and Practical Implications

May 12, 2026

Webinar

Workshop

Protecting Innovation in the Life Sciences: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law

May 7, 2026

Cambridge

Ad Law Buzz Blog

How to Survive a Section 230 Defense: Recent Cases Provide Guidance

May 1, 2026

Panel Discussion

2026 World IP Day Event – Women in Intellectual Property Law: Opportunities and Challenges

April 24, 2026

Virtual

Conference

2026 American Bar Association-Intellectual Property Law Section Annual Meeting

April 15-16, 2026

Washington, DC

Hybrid Conference

2026 Patent Law Institute: Critical Issues & Best Practices

April 9-10, 2026

San Francisco

Conference

2026 Women’s Power Summit on Law & Leadership

April 8-10, 2026

Austin

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP